← The Wire
NUVLNasdaq
Nuvalent, Inc.
Pharmaceutical Preparations · DE · CIK 1861560
Nuvalent creates precisely targeted small molecule therapies for cancer patients, aiming to overcome limitations of existing treatments
🔥 High media attention
$9.75B
Market cap
$123.51
Last close
-0.0%
1D
+0.1%
5D
1.3M
Volume
Price · last 39 sessions+20.4%
May 4L $88.49 · H $123.58Jun 29
108
Total filings
Jun 18, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteJun 18, 20268-KMaterial Agreement · Reg FD DisclosureJun 9, 202610-Q10-QMay 7, 20268-KResults of OperationsMay 7, 2026DEFA14ADEFA14AApr 28, 2026DEF 14ADEF 14AApr 28, 20268-KCompany UpdateApr 7, 202610-K10-KFeb 26, 20268-KResults of OperationsFeb 26, 20268-KResults of OperationsJan 14, 20268-KCompany UpdateDec 16, 20258-KExecutive ChangeDec 10, 20258-KMaterial Agreement · Company UpdateNov 20, 2025424B5424B5Nov 19, 2025424B5424B5Nov 17, 20258-KCompany UpdateNov 17, 202510-Q10-QOct 30, 20258-KResults of OperationsOct 30, 20258-KCompany UpdateSep 22, 202510-Q10-QAug 7, 20258-KResults of OperationsAug 7, 20258-KCompany UpdateJul 21, 20258-KCompany UpdateJun 24, 20258-KExecutive Change · Shareholder VoteJun 20, 20258-KExecutive ChangeJun 10, 202510-Q10-QMay 8, 20258-KResults of OperationsMay 8, 2025DEFA14ADEFA14AApr 28, 2025DEF 14ADEF 14AApr 28, 20258-KExecutive ChangeApr 17, 202510-K10-KFeb 27, 20258-KResults of OperationsFeb 27, 20258-KCompany UpdateJan 14, 20258-KExecutive ChangeDec 9, 202410-Q10-QNov 12, 20248-KResults of OperationsNov 12, 2024SC 13GSC 13GNov 8, 2024SC 13GSC 13GOct 24, 20248-KMaterial Agreement · Company UpdateSep 17, 2024424B5424B5Sep 17, 2024424B5424B5Sep 16, 20248-KCompany UpdateSep 16, 202410-Q10-QAug 8, 20248-KResults of OperationsAug 8, 20248-KCompany UpdateJul 22, 20248-KShareholder VoteJun 14, 20248-KCompany UpdateMay 16, 202410-Q10-QMay 9, 20248-KResults of OperationsMay 9, 2024DEFA14ADEFA14AApr 26, 2024DEF 14ADEF 14AApr 26, 202410-K10-KFeb 27, 20248-KResults of OperationsFeb 27, 2024SC 13GSCHEDULE 13GFeb 13, 20248-KResults of OperationsJan 9, 2024SC 13GSC 13GJan 2, 202410-Q10-QNov 14, 20238-KResults of OperationsNov 14, 2023SC 13GSC 13GOct 30, 20238-KMaterial Agreement · Company UpdateOct 17, 2023424B5424B5Oct 17, 2023424B5424B5Oct 16, 20238-KCompany UpdateOct 13, 20238-KCompany UpdateOct 4, 202310-Q10-QAug 10, 20238-KResults of OperationsAug 10, 20238-KBylaw Amendment · Shareholder VoteJun 16, 202310-Q10-QMay 11, 20238-KResults of OperationsMay 11, 2023DEFA14ADEFA14AApr 28, 2023DEF 14ADEF 14AApr 28, 202310-K10-KMar 16, 20238-KResults of OperationsMar 16, 20238-KReg FD DisclosureMar 13, 202310-Q10-QNov 10, 20228-KResults of OperationsNov 10, 2022SC 13GSC 13GNov 9, 20228-KMaterial Agreement · Company UpdateNov 1, 2022424B5424B5Nov 1, 2022424B5424B5Nov 1, 2022
Insider Activity
In the 90 days to Mar 26, 2026: 6 sold $20.2M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 26, 2026 | Miller Deborah AnnChief Legal Officer | Sell | 2,803 | $99.46 | $279K |
| Mar 26, 2026 | Miller Deborah AnnChief Legal Officer | Sell | 1,757 | $98.21 | $173K |
| Mar 26, 2026 | Miller Deborah AnnChief Legal Officer | Sell | 940 | $97.50 | $92K |
| Mar 25, 2026 | Balcom AlexandraChief Financial Officer | Sell | 13,700 | $100.16 | $1.4M |
| Mar 24, 2026 | Balcom AlexandraChief Financial Officer | Sell | 7,671 | $95.88 | $735K |
| Mar 24, 2026 | Balcom AlexandraChief Financial Officer | Sell | 2,599 | $95.03 | $247K |
| Mar 24, 2026 | Balcom AlexandraChief Financial Officer | Sell | 1,160 | $96.50 | $112K |
| Mar 13, 2026 | Pelish Henry E.Chief Scientific Officer | Sell | 2,597 | $98.83 | $257K |
| Mar 13, 2026 | Pelish Henry E.Chief Scientific Officer | Sell | 1,703 | $99.71 | $170K |
| Mar 13, 2026 | Pelish Henry E.Chief Scientific Officer | Sell | 804 | $97.89 | $79K |
| Mar 12, 2026 | Pelish Henry E.Chief Scientific Officer | Sell | 24,189 | $97.79 | $2.4M |
| Mar 12, 2026 | Pelish Henry E.Chief Scientific Officer | Sell | 5,505 | $98.44 | $542K |
| Mar 12, 2026 | Pelish Henry E.Chief Scientific Officer | Sell | 306 | $99.12 | $30K |
| Mar 6, 2026 | Porter James RichardPresident and CEO | Sell | 16,015 | $99.29 | $1.6M |
| Mar 6, 2026 | Porter James RichardPresident and CEO | Sell | 13,585 | $98.59 | $1.3M |
| Mar 6, 2026 | Porter James RichardPresident and CEO | Sell | 400 | $100.19 | $40K |
| Feb 26, 2026 | Noci DarleneChief Development Officer | Sell | 3,000 | $102.64 | $308K |
| Feb 26, 2026 | Miller Deborah AnnChief Legal Officer | Sell | 2,698 | $102.64 | $277K |
| Feb 26, 2026 | Miller Deborah AnnChief Legal Officer | Sell | 2,602 | $103.41 | $269K |
| Feb 26, 2026 | Noci DarleneChief Development Officer | Sell | 2,300 | $103.44 | $238K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
🔥 High media attentionCoverage (30d): 8 reputable articles · skews ▲ positive.
ReutersGSK boosts cancer portfolio with $10.6 billion Nuvalent takeover20d agoInvestor's Business DailySmall Biotech Catapults To Record High On $10.6 Billion Deal20d agoReutersUK's FTSE 100 hits over three-week low as banks, energy stocks sag20d agoBloomberg.comUS Premarket Movers for June 9, 202621d agoCNBCStocks making the biggest moves premarket: GSK, Nuvalent, J.M. Smucker, SailPoint and more21d agoWSJGSK to Buy Nuvalent for $10.6 Billion in Oncology Push21d ago
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance